At in vitro drug concentrations greater than 10 μM, the clinical applicability of a compound becomes questionable and as such, we did not further explore the potential of PARP-ATM inhibition as a combination across different pediatric tumor types. The gene discussed is PARP1; the disease is neoplasm.